Seres Therapeutics (MCRB) Capital Expenditures (2014 - 2025)
Seres Therapeutics (MCRB) posted Capital Expenditures of $29000.0 for Q4 2025, up 262.5% sequentially from $8000.0 in Q3 2025, and up 110.0% YoY from $13809.5 in Q4 2024.
Seres Therapeutics (MCRB) Capital Expenditures (2014 - 2025) Analysis & Trends
Seres Therapeutics has reported Capital Expenditures for 12 years, with the latest figure at $29000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 110.0% year-over-year to $29000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $197000.0 (up 258.18% YoY) and the FY2025 annual result came in at $252000.0, changed N/A from the prior year.
- Capital Expenditures grew to $29000.0 in Q4 2025 per MCRB's latest filing, from $8000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $4.5 million in Q2 2022 and troughed at -$4.9 million in Q3 2023.
- A 5-year average of $609055.6 and a median of $279000.0 in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2023: Capital Expenditures jumped 6860.0% in 2021, then slumped 495.43% in 2023.
- Over 5 years, Capital Expenditures stood at $558000.0 in 2021, then soared by 520.25% to $3.5 million in 2022, then slumped by 110.23% to -$354000.0 in 2023, then gained by 18.08% to -$290000.0 in 2024, then soared by 110.0% to $29000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $29000.0, $8000.0, and $160000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Dec 31, 2024 | -290,000.00 |
| Dec 31, 2024 | -290,000.00 |
| Sep 30, 2024 | 290,000.00 |
| Sep 30, 2024 | 290,000.00 |
| Dec 31, 2023 | -354,000.00 |
| Dec 31, 2023 | -354,000.00 |
| Sep 30, 2023 | -4.93 Mn |
| Sep 30, 2023 | -4.93 Mn |
| Jun 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 4.37 Mn |
| Mar 31, 2023 | 928,000.00 |
| Mar 31, 2023 | 928,000.00 |